Answering the Questions: Clinical Considerations in the Use of Integrase Inhibitors

Faculty:

William G. Powderly, MD Paul E. Sax, MD Jonathan M. Schapiro, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Recount strategies to maximize the likelihood of achieving virologic suppression with integrase inhibitors in treatment-experienced patients
• Describe situations in which integrase inhibitors may be considered in first-line therapy
• Discuss considerations when switching an agent in a virologically suppressive regimen to raltegravir
• Explain the clinical relevance of integrase inhibitor resistance seen upon virologic failure

Topics covered include:

• Integrase Inhibitors in Treatment-Experienced Patients
• Integrase Inhibitors in Treatment-Naive Patients
• Integrase Inhibitors as Second-Line Therapy and Switch Agents
• Safety, Tolerability, and Resistance to Integrase Inhibitors

Abstract

• Click here to view abstract